The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2885-2892

  Hohaus, Stefan ^a   Santangelo, Rosaria ^a   Giachelia, Manuela ^a   Vannata, Barbara ^a   Massini, Giuseppina ^a   Cuccaro, Annarosa ^a   Martini, Maurizio ^a   Cesarini, Valeriana ^a   Cenci, Tonia ^a   D'Alo, Francesco ^a   Voso, Maria Teresa ^a   Fadda, Giovanni ^a   Leone, Giuseppe ^a   Larocca, Luigi M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; INTERLEUKIN 6; VIRUS DNA; VIRUS RNA;

ADOLESCENT; ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA DETERMINATION; EPSTEIN BARR VIRUS; FEMALE; GENE NUMBER; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; LYMPH NODE BIOPSY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REED STERNBERG CELL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; VIRUS DETECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 79955493270     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3327     Document Type: Article

References (38)

1. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-12. (Pubitemid 37328658)
2. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007;38:1293-1304. (Pubitemid 47247493)
3. Gandhi MK, Tellam JT, Khanna R. Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 2004;125:267-81. (Pubitemid 38621759)
4. Massini G, Siemer D, Hohaus S. EBV in Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2009;1:e2009013.
5. Hjalgrim H, Engels EA. Infectious aetiology of Hodgkin and non- Hodgkin lymphomas: a review of the epidemiological evidence. J Intern Med 2008;264:537-48.
6. Jarrett RF, Krajewski AS, Angus B, Freeland J, Taylor PR, Taylor GM, et al. The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates. J Clin Pathol 2003;56:811-6. (Pubitemid 37386566)
7. Dolcetti R, Boiocchi M, Gloghini A, Carbone A. Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 2001;37:1276-87. (Pubitemid 32553772)
8. Jarrett R. Viruses and Hodgkin's lymphoma. Ann Oncol 2002;13Suppl 1:23-9. (Pubitemid 34567397)
9. Henle W, Henle G, Andersson J, Ernberg I, Klein G, Horwitz CA, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A 1987;84:570-4. (Pubitemid 17006237)
10. Chang ET, Zheng T, Lennette ET, Weir EG, Borowitz M, Mann RB, et al. Heterogeneity of risk factors and antibody profiles in epstein-barr virus genome-positive and -negative hodgkin lymphoma. J Infect Dis 2004;189:2271-8.
11. Khan G, Lake A, Shield L, Freeland J, Andrew L, Alexander FE, et al. Phenotype and frequency of Epstein-Barr virus-infected cells in pretreatment blood samples from patients with Hodgkin lymphoma. Br J Haematol 2005;129:511-9. (Pubitemid 40769900)
12. Gallagher A, Armstrong AA, MacKenzie J, Shield L, Khan G, Lake A, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999;84:442-8. (Pubitemid 29337135)
13. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol 2009;20:1408-13.
14. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006;12:460-4. (Pubitemid 43166136)
15. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 2000;111:239-46.
16. Drouet E, Brousset P, Fares F, Icart J, Verniol C, Meggetto F, et al. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J Med Virol 1999;57:383-9. (Pubitemid 29124258)
17. Wagner HJ, Schläger F, Claviez A, Bucsky P. Detection of Epstein- Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction. Eur J Cancer 2001;37:1853-7. (Pubitemid 32913311)
18. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-97. (Pubitemid 34627193)
19. Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007;25:1732-40. (Pubitemid 46797954)
20. Sánchez-Aguilera A, Montalbán C, de la Cueva P, Sánchez-Verde L, Morente MM, García-Cosío M, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662-8. (Pubitemid 44061368)
21. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-85.
22. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14. (Pubitemid 28543499)
23. Larocca LM, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998;92:1011-9. (Pubitemid 28355486)
24. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768-75. (Pubitemid 28194317)
25. Herbst H, Samol J, Foss HD, Raff T, Niedobitek G. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol 1997;182:299-306. (Pubitemid 27285782)
26. Biggar RJ, Johansen JS, Smedby KE, Rostgaard K, Chang ET, Adami HO, et al. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res 2008;14:6974-8.
27. Hohaus S, Giachelia M, Massini G, Vannata B, Criscuolo M, Martini M, et al. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res 2009;33:1352-6.
28. Choi JJ, Reich CF III, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 2005;115:55-62 (Pubitemid 40593291)
29. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008;222:155-61. (Pubitemid 351430369)
30. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73. (Pubitemid 41688920)
31. Glavina-Durdov M, Jakic-Razumovic J, Capkun V, Murray P. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer 2001;84:1227-34. (Pubitemid 32511341)
32. Flavell KJ, Billingham LJ, Biddulph JP, Gray L, Flavell JR, Constandinou CM, et al. The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Ann Oncol 2003;14:282-90. (Pubitemid 36305442)
33. Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS, et al. Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 2005;106:2444-51.
34. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005;23:7604-13. (Pubitemid 46291824)
35. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009;27:3815-21.
36. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med 1989;320:689-95. (Pubitemid 19072487)
37. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus +Hodgkin's disease. J Exp Med 2004;200:1623-33. (Pubitemid 40094186)
38. Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, et al. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007;17:203-10.